Table 7.34Summary of published economic analyses

StudyDisease duration (years)Country (sponsor)TNF inhibitor(s) consideredForm of economic analysisModel usedTime horizon
Choi et al. (2002)306USA (Not Stated)EtanerceptCost-effectivenessDecision tree6 months
Brennan et al. (2004)307Not given Failed 3.3. DMARDsUK (Not Stated, by two authors from Wyeth)EtanerceptCost-utilityPatient levelLifetime
Wong et al. (2002)308Not statedUSA (Schering-Plough, Centocor Corp, National Institutes for Health)InfliximabCost-utilityMarkovLifetime
Kobelt et al. (2003)309Response: 11yrs
Baseline: 8.2 months
Sweden and UK (Schering-Plough)InfliximabCost-utilityMarkov10 years
Kobelt et al. (2004)31014.2Sweden (Österlund and Kock Foundations, the King Gustav V 80-year fund, Reumatikerförbundet.)Etanercept, infliximabCost utilityNot applicableNot applicable
Chiou et al. (2004)311USA (Not stated)Etanercept, infliximab, adalimumabCost-utilityDecision tree1 year
Welsing et al. (2004)3123.8 minimumNetherlands (Not stated, but used data from Wyeth)EtanerceptCost-utilityMarkov5 years
Bansback et al. (2005)313Over 8yrsSweden (Abbott Laboratories)Etanercept, infliximab, adalimumabCost-utilityPatient levelLifetime
Kobelt et al. (2005)3146.8Sweden (Wyeth Research)EtanerceptCost-utilityMarkov10 years
Spalding et al. (2006)2393 monthsUSA (Astellas Pharma)Adalimumab, etanercept, infliximab + methotrexate, adalimumab + methotrexateCost utilityMarkovLifetime
Tanno et al. (2006)31511Japan (Ministry of Education, Science, Sports and Culture and the Ministry of Health, Japan)EtanerceptCost utilityMarkovLifetime
Marra et al. (2007)3169Canada (Canadian Arthritis Network)Infliximab + methotrexateCost utilityMarkov10 years
Chen et al. (2006)237VariousUK (NHS HTA Programme)Adalimumab, etanercept, infliximab + methotrexate, adalimumab + methotrexate, etanercept+ methotrexateCost utilityPatient levelLifetime
Brennan et al. (2007)31714.1UK (BSR)Etanercept, infliximab, adalimumabCost utilityPatient levelLifetime

From: 7, Pharmacological management

Cover of Rheumatoid Arthritis
Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults.
NICE Clinical Guidelines, No. 79.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2009, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.